Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...
In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in ...
Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) ...
Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the ...
India’s pharmaceutical giants are hoping to earn fat profits as their customers get thinner. With the patent for blockbuster diabetes and weight-loss drugs Ozempic and Wegovy set to expire in March, ...
Novo Nordisk announces phase 2 clinical trial results of amycretin in people with type 2 diabetes: Bagsværd, Denmark Thursday, November 27, 2025, 13:00 Hrs [IST] Novo Nordisk, a ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Zacks Investment Research on MSN
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback